Skip to main content

JHOP - October 2021 Vol 11, No 5

Editorial
Case Reports
Original Research
Review Article
FDA Updates
Editorial
Editorial, Chemotherapy, Oncology Pharmacy Programs/Protocols, Methotrexate
Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?
Joseph Bubalo, PharmD, BCPS, BCOP
Read More
Case Reports
Case Reports, Adverse Events, Melanoma, Checkpoint Inhibitors
Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine
Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD
Read More
Original Research
Original Research, COVID-19, Technology
Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic
Colleen Bohnenkamp, PharmD, BCOP, BCPS; Grace A. Martin, PharmD, BCOP; Laure Dubois, PharmD, BCOP; Olivia Fahey, PharmD, BCOP; Jade Hefler, PharmD
Read More
Original Research, Renal-Cell Carcinoma, Targeted Therapies, Oral Therapy
Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment
Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP
Read More
Original Research, Chemotherapy, Dose Escalation/Reduction, Oncology Pharmacy Programs/Protocols, Methotrexate
Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate
Christopher Sinoimeri, PharmD; Matthew Lei, PharmD, BCOP; Stephanie Monaco, PharmD, BCOP; Uvette Lou, PharmD, BCOP
Read More
Review Article
Review Article, Bladder Cancer, Targeted Therapies
Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma
Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP
Read More
FDA Updates
Online First
FDA Updates
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
Read More
Online First
FDA Updates
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Read More
Online First
FDA Updates
Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease
Read More
Online First
FDA Updates
Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease
Read More
Online First
FDA Updates
Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease
Read More
Online First
FDA Updates
Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
Read More
FDA Updates
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
Read More
Online First
FDA Updates
Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma
Read More
Online First
FDA Updates
Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors
Read More
Online First
FDA Updates
Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma
Read More